haidut
Member
As promised, I finally got around to releasing the unicorn of the anti-serotonin world - i.e. the chemical known as ritanserin. It does not have a trade name as it is a research/lab chemical only and was never submitted for approval by the FDA. However, research with ritanserin is thriving and there are quite a few studies and even humans trials. Ritanserin was developed as an alternative to cyproheptadine with the goal of causing less sedation, having less anti-cholinergic effects, and no antagonism to dopamine "receptors". In fact, ritanserin has been found to have a pronounced pro-dopamine effect and robustly increases libido in animals models, which is consistent with its dopaminergic effects.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1290899/pdf/jrsocmed00173-0013.pdf
"...Ritanserin is the first extremely potent, specific and pure serotonin-S2 antagonist that passes the blood-brain barrier easily. It belongs to a new series of chemically related compounds of which ketanserin, a peripherally acting 5-HT2 receptor antagonist under clinical investigation for cardiovascular diseases, is the prototype. From the receptor binding point of view [31], the most remarkable feature of ritanserin is its high binding affinity for serotonin-S2 receptors. In rat frontal cortex, only 0.9 nmol concentration of ritanserin is needed to displace the ligand ketanserin from the receptor binding sites. The IC50 values for binding to other sites (histamine H1, dopamine-D2, a, and a2-adrenergic sites) are so much higher that they are of no pharmacological importance. The fact that ritanserin is devoid of any dopamine-D2 antagonism means that it is devoid of any neuroleptic activity."
However, please note that similar to the products sold by companies like BluePeptides, this product if for lab/research use only. The product can be ordered from the link below:
IdeaLabs Online Store - Worldwide Ordering And Delivery - Laboratory Research Chemicals
*******************************************************************************
Ritanserin is a potent general serotonin antagonist targeting mostly the 5-HT2 receptor, as well as the 5-HT1, 5-HT5, 5-HT6, and 5-HT7, H1, and alpha1 / alpha2 adrenergic receptors. Ritanserin is extensively used in clinical and experimental studies and is widely considered the most selective antagonist of serotonin "receptors" when used in the appropriate dose range. It has no known dopamine antagonism when used in relevant pharmacological doses.
Drops per container: about 360
Each drop contains the following ingredients:
Ritanserin: 0.5 mg
Other ingredients: DMSO, ethanol
*******************************************************************************
References:
Ritanserin - Wikipedia, the free encyclopedia
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. - PubMed - NCBI
Ritanserin improves sleep quality in narcolepsy. - PubMed - NCBI
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. - PubMed - NCBI
[Ritanserin in autistic children]. - PubMed - NCBI
Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. - PubMed - NCBI
Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. - PubMed - NCBI
A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. - PubMed - NCBI
Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. - PubMed - NCBI
Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanseri... - PubMed - NCBI
Ritanserin, a 5-HT2 receptor antagonist, increases subcortical blood flow following photothrombotic middle cerebral artery occlusion in rats. - PubMed - NCBI
A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangl... - PubMed - NCBI
Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans. - PubMed - NCBI
Potential therapeutic effects of ritanserin in Cushing's disease. - PubMed - NCBI
Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. - PubMed - NCBI
Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. - PubMed - NCBI
Effect of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions. - PubMed - NCBI
Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. - PubMed - NCBI
Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. - PubMed - NCBI
The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hy... - PubMed - NCBI
Serotonin antagonism in panic disorder: an open trial with ritanserin. - PubMed - NCBI
Serotonin as a modulator of skeletal muscle oxygenation: effects of ketanserin and ritanserin on oxygen pressure distributions. - PubMed - NCBI
Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night? - PubMed - NCBI
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. - PubMed - NCBI
Facilitatory effect of ritanserin is mediated by dopamine D(1) receptors on olfactory learning in young rats. - PubMed - NCBI
Behavioral and neuroendocrine assessment of ritanserin exposure in the developing chicken: lack of toxicity at effective doses. - PubMed - NCBI
Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. - PubMed - NCBI
Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. - PubMed - NCBI
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1290899/pdf/jrsocmed00173-0013.pdf
"...Ritanserin is the first extremely potent, specific and pure serotonin-S2 antagonist that passes the blood-brain barrier easily. It belongs to a new series of chemically related compounds of which ketanserin, a peripherally acting 5-HT2 receptor antagonist under clinical investigation for cardiovascular diseases, is the prototype. From the receptor binding point of view [31], the most remarkable feature of ritanserin is its high binding affinity for serotonin-S2 receptors. In rat frontal cortex, only 0.9 nmol concentration of ritanserin is needed to displace the ligand ketanserin from the receptor binding sites. The IC50 values for binding to other sites (histamine H1, dopamine-D2, a, and a2-adrenergic sites) are so much higher that they are of no pharmacological importance. The fact that ritanserin is devoid of any dopamine-D2 antagonism means that it is devoid of any neuroleptic activity."
However, please note that similar to the products sold by companies like BluePeptides, this product if for lab/research use only. The product can be ordered from the link below:
IdeaLabs Online Store - Worldwide Ordering And Delivery - Laboratory Research Chemicals
*******************************************************************************
Ritanserin is a potent general serotonin antagonist targeting mostly the 5-HT2 receptor, as well as the 5-HT1, 5-HT5, 5-HT6, and 5-HT7, H1, and alpha1 / alpha2 adrenergic receptors. Ritanserin is extensively used in clinical and experimental studies and is widely considered the most selective antagonist of serotonin "receptors" when used in the appropriate dose range. It has no known dopamine antagonism when used in relevant pharmacological doses.
Drops per container: about 360
Each drop contains the following ingredients:
Ritanserin: 0.5 mg
Other ingredients: DMSO, ethanol
*******************************************************************************
References:
Ritanserin - Wikipedia, the free encyclopedia
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. - PubMed - NCBI
Ritanserin improves sleep quality in narcolepsy. - PubMed - NCBI
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. - PubMed - NCBI
[Ritanserin in autistic children]. - PubMed - NCBI
Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. - PubMed - NCBI
Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. - PubMed - NCBI
A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. - PubMed - NCBI
Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. - PubMed - NCBI
Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanseri... - PubMed - NCBI
Ritanserin, a 5-HT2 receptor antagonist, increases subcortical blood flow following photothrombotic middle cerebral artery occlusion in rats. - PubMed - NCBI
A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangl... - PubMed - NCBI
Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans. - PubMed - NCBI
Potential therapeutic effects of ritanserin in Cushing's disease. - PubMed - NCBI
Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. - PubMed - NCBI
Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. - PubMed - NCBI
Effect of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions. - PubMed - NCBI
Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. - PubMed - NCBI
Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. - PubMed - NCBI
The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hy... - PubMed - NCBI
Serotonin antagonism in panic disorder: an open trial with ritanserin. - PubMed - NCBI
Serotonin as a modulator of skeletal muscle oxygenation: effects of ketanserin and ritanserin on oxygen pressure distributions. - PubMed - NCBI
Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night? - PubMed - NCBI
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. - PubMed - NCBI
Facilitatory effect of ritanserin is mediated by dopamine D(1) receptors on olfactory learning in young rats. - PubMed - NCBI
Behavioral and neuroendocrine assessment of ritanserin exposure in the developing chicken: lack of toxicity at effective doses. - PubMed - NCBI
Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. - PubMed - NCBI
Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. - PubMed - NCBI
Last edited: